Unlock instant, AI-driven research and patent intelligence for your innovation.

Camptothecine derivatives and their use

A technology of camptothecin and derivatives, which is applied in the field of new anti-tumor drug compounds, and can solve the problems of anti-tumor activity and low toxicity.

Inactive Publication Date: 2007-06-06
HEFEI KEDA BIO TECH CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the antitumor activity and low toxicity of these new derivatives of camptothecin are still not ideal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Camptothecine derivatives and their use
  • Camptothecine derivatives and their use
  • Camptothecine derivatives and their use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0142] Example 1: Preparation of N-(3-aminopropyl) morpholine to the ammonolysis ring-opening product (1) XY-8 of CPT

[0143] 105 mg (0.3 mmol) of CPT was dissolved in 15 ml of methanol, and 1.2 equivalents of ammonolysis reagent N-(3-aminopropyl) morpholine (3) a was added. After reacting for 14 hours at 75° C., the system became clear, and the reaction mixture was Poured into diethyl ether, a yellow precipitate was precipitated, which was filtered off and washed with cold diethyl ether. It can be seen from TLC that the product contains unreacted CPT. Dissolve the product in a small amount of CHCl 3 , separated by alumina column chromatography (eluent: ethyl acetate:petroleum ether=1:1→4:1) to obtain 106 mg of pure ring-opened product (1) XY-8, yield 88%.

[0144] IR(KBr)ν: 1620.61cm -1 (-CONH-).

[0145] 1 HNMR (CDCl 3 , 300MHz) δppm: 1.07 (t, J=7.20Hz, 3H, 18-CH 3 ), 1.76 (m, 2H, 19-CH 2 ), 2.25(m, 1H, 22-CH 2 ), 2.43 (m, 1H, 22-CH 2 ), 2.44(m, 6H, 22-CH 2 , and 2...

Embodiment 2

[0146] Example 2, the preparation of the 17-hydroxyacetylation product (1) Bam of the ammonia solution ring-opening product of CPT (1) XY-8

[0147] 126 mg of N-(3-aminopropyl) morpholine CPT ring-opened product (1) XY-8 (0.25 mmol) was dissolved in 2 mL (24.8 mmol) of pyridine, 1 mL (10.6 mmol) of acetic anhydride was added, and the temperature was maintained by heating Stir overnight at around 40°C. The solvent was evaporated under reduced pressure. The residue was washed with a small amount of CHCl 3 Dissolve, pour into 20mL petroleum ether and diethyl ether equal volume mixture, precipitate precipitate, filter, wash with cold diethyl ether. Reuse CHCl 3 Dissolved and purified by silica gel column chromatography (eluent: ethyl acetate:petroleum ether=2:1→pure ethyl acetate) to obtain 112mg of yellow solid powder (1) Bam. Yield 81.9%.

[0148] IR(KBr)ν: 1733.69cm -1 (-CO-CH 3 ), 1620.61cm -1 (-CONH-).

[0149] 1 HNMR (CDCl 3 , 300MHz) δppm: 1.10 (t, J=7.17Hz, 3H, ...

Embodiment 3

[0150] Example 3, Preparation of the 17-hydroxypropionylation product (1) Ban of the ammonia-cleaved ring-opening product (1) XY-8 of CPT

[0151] 150 mg (0.30 mmol) of the CPT ring-opened product (1) XY-8 of N-(3-aminopropyl) morpholine, 1.5 mL of pyridine (18.6 mmol) and 1 mL of propionic anhydride (7.7 mmol) were mixed and heated to 40 ° C, stirred Overnight, the low-boiling solvent was evaporated, and the residue was poured into 50 mL of diethyl ether to precipitate a pale yellow solid, which was further purified by silica gel column chromatography (eluent: ethyl acetate:petroleum ether=1:1→3:1) to obtain (1 ) Bam pure product 111 mg, yield 66.4%.

[0152] IR(KBr)ν: 1729.83cm -1 (-COCH 2 CH 3 ), 1654.52cm -1 (-CONH-)

[0153] 1 HNMR.(CDCl 3 , 300MHz) δppm: 1.11 (t, J=7.23Hz, 3H, 18-CH 3 ), 1.21(t, J=7.05Hz, 3H, -CO-C-CH 3 ), 1.77 (m, 2H, 19-CH 2 ), 2.31(m, 1H, 1 / 2×22-CH 2 ), 2.40~2.15(m, 1H, 1 / 2×22-CH 2 ), 2.55~2.56 (m, 6H, 23-CH 2 and 2×24-CH 2 ), 3.32(m, 1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to View More

Abstract

The present invention provides camptothecine derivatives shown in the expression and their salts. The present invention also provides the preparation process of the derivatives and their use in treating cancers.

Description

Technical field: [0001] The present invention relates to a new antitumor drug compound, especially a new derivative of camptothecin, their preparation and application. Background technique: [0002] Some new derivatives with activity equal to or better than camptothecin and less toxic than camptothecin have been found among the compounds whose E lactone ring is opened. Some of them are soluble in water, so they are suitable for making more convenient dosage forms such as injections. For example, Japan's Daiichi Pharmaceutical Company used NH 2 CH 2 CH 2 N(CH 3 ) 2 A series of new ring-opening compounds of the E ring are obtained by performing a ring-opening reaction on the E ring, and then acylating the 17-hydroxyl group (see J.P.A, H1 131179; CN1126212A). Italy's Indena S.P.A. company makes the E ring opening of camptothecin to generate alkali metal carboxylate by alkaline hydrolysis, and then 17-hydroxyl acylation, also obtains a series of new water-soluble camptothe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D471/22C07D221/00C07D209/00A61K31/47A61P35/00
Inventor 尤田耙袁胜涛王涛张陆勇王宗贵耿燕李明宗
Owner HEFEI KEDA BIO TECH CO LTD